Role of home monitoring with iCare ONE rebound tonometer in glaucoma patients management

AIM: To evaluate intraocular pressure (IOP) measurements and fluctuations using the iCare ONE rebound tonometer (RT-ONE), during home monitoring, in diagnosed and suspected glaucoma patients. METHODS: A retrospective case series of consecutive patients with known glaucoma or glaucoma suspects who were followed-up and treated between January 2016 and January 2017. The study included 80 eyes of 40 patients with a mean age of 59.1±14.6y (range, 24-78). All patients have undergone 4-5d of IOP home monitoring with RT-ONE at morning, noon, afternoon, and night time. RESULTS: Baseline mean IOP, as measured in the clinic (8 a.m.-12 p.m.), was 17.4±5.1 mm Hg, compared to RT-ONE home monitoring mean IOP of 15.6±4.1 mm Hg (P=0.002). Mean IOP was significantly lower at noon, afternoon and night times compared to clinic measured IOP and morning measurements (P=0.005). IOP peak measured during home monitoring was significantly higher compared to the clinic measured IOP (21.3±5.6 mm Hg and 17.4±5.1 mm Hg, P<0.001). IOP peaks during home monitoring demonstrated a majority of 47 peaks during morning measurements, compared to 23 at noon, 19 at afternoon and only 12 at night (P<0.001). The home monitoring results led to treatment modification of 44 eyes (55%), treatment regime was insufficient for 40 (50%) eyes. CONCLUSION: Home monitoring IOP with RT-ONE can provide good assessment of mean IOP, IOP fluctuations and peaks throughout the hours of the day, which lead to an accurate treatment for glaucoma patients.

IOP-lowering therapy evaluation using 24-hour IOP monitoring

When choosing a medication, a doctor has to be sure in its efficacy and safety for the patient. The conduct of multiple post-registration studies on different aspects of medications’ use is aimed at helping the clinician to correctly evaluate the therapeutic potential of proposed medications. The aim of present study is to evaluate the IOP-lowering efficacy and tolerability of Glauprost, Duoprost, Dorzopt Plus in POAG patients according to 24-hour IOP monitoring data by circadian rhythms measured with Icare one tonometer. The IOP monitoring by circadian rhythms allowed obtaining considerably more data for IOP-lowering efficacy evaluation in comparison with single IOP measurement using Maklakov tonometer. This increases the IOP-lowering efficacy evaluation accuracy.